|
|
| The present Competitive Intelligence report about IGF-1/R Antagonists provides a competitor evaluation in the field of novel molecular entities directed against the insulin-like growth factor-1 receptor (IGF-1R) or its ligands IGF-1 and IGF-2 for treatment of cancer as of June 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Access data will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of current active projects in research and development of IGF-1/R Antagonists in oncology. In addition, the report lists company-specific R&D pipelines of IGF-1/R antagonists. Competitor projects are listed in a tabular format providing information on:
|
Additional Information
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Related Markets
Oncology/Hematology Reports
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors

